Key elements of our corporate strategy include:

• Focus on highly prevalent anxiety, depression and neurological disorders affecting both adult and pediatric populations where the current standard of care is inadequate to meet patient needs.
• Emphasize development and commercialization of CNS product candidates with potential for rapid-onset therapeutic effects, exceptional safety and tolerability, and significant commercial potential in multiple CNS indications in global markets with currently limited or inadequate treatment options;
• Continue internal research and development efforts to evaluate the expanded therapeutic and commercial potential for our existing CNS product candidates in the treatment of additional CNS indications and identify additional CNS drug candidates for our CNS product portfolio;
• Pursue global development, on our own in the U.S. and on our own or with collaborators outside the U.S., of novel CNS product candidates which are fundamentally differentiated from currently approved therapies; and
• Commercialize on our own, and retain all commercial rights to, our CNS product candidates in the U.S. and partner with highly qualified third-party collaborators for commercialization of our CNS product candidates outside the U.S.